J&J buys eye disease gene therapy from MeiraGTx, giving the biotech the cash infusion it was seeking

21 Dec 2023

License out/inGene TherapyPhase 3

Johnson & Johnson purchased a gene therapy for X-linked retinitis pigmentosa from MeiraGTx for $65 million upfront, the biotech announced Thursday. The deal, which also comes with a commercial supply agreement, could be worth up to $415 million, including another $65 million in milestone payments expected in 2024 and up to $285 million upon first sales of the gene therapy in the US and EU. J&J was already sponsoring a Phase III trial for the gene therapy candidate known as botaretigene sparoparvovec, or bota-vec for short. In 2019, J&J struck a licensing deal with MeiraGTx around three eye disease programs, including bota-vec, and paid $100 million upfront .

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Johnson & Johnson

MeiraGTx Holdings Plc

Indications

Eye DiseasesX-linked retinitis pigmentosa

Targets

Drugs

A-004Pexastimogene devacirepvec

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.